Conjugates of biomolecules to nanoparticles

US11015220B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11015220-B2
Application numberUS-201816123166-A
CountryUS
Kind codeB2
Filing dateSep 6, 2018
Priority dateMar 27, 2009
Publication dateMay 25, 2021
Grant dateMay 25, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity. Such conjugates can exhibit reduced aggregation and improved stochiometries wherein the average biomolecule:nanoparticle ratio approaches or equals 1:1. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition, comprising a population of polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the population of polymerase-nanoparticle conjugates has an average of about 0.5 to 1.5 polymerases per nanoparticle and wherein the conjugate has polymerase activity that is at least 70%-relative to the polymerase activity of the unconjugated polymerase; wherein the nanoparticle is capable of generating a detectable signal. 2. The composition of claim 1 , wherein the polymerase activity of the conjugate is at least 80%, 90%, 95%, 97% or 99% relative to the polymerase activity of the unconjugated polymerase. 3. The composition of claim 1 , wherein there is a 1:1 correspondence between the polymerase and the nanoparticle. 4. The composition of claim 1 , further comprising an accessory compound selected from among uracil DNA glycosylase, uracil DNA glycosylase inhibitor maltose binding protein, albumin, avidin, chloramphenicol acetyltransferase, horseradish peroxidase, glutathione S-transferase and mucin. 5. The composition of claim 3 , further comprising an accessory compound selected from among uracil DNA glycosylase, uracil DNA glycosylase inhibitor, maltose binding protein, albumin, avidin, chloramphenicol acetyltransferase, horseradish peroxidase, glutathione S-transferase and mucin. 6. The composition of claim 4 , wherein the accessory compound is attached to the nanoparticle. 7. The composition of claim 6 , wherein the accessory compound is a protein that does not react with the polymerase or nucleotides. 8. The composition of claim 4 , wherein the accessory compound further comprises a His tag. 9. The composition of claim 1 , wherein the nanoparticle is positioned relative to the polymerase to perform an energy transfer reaction with a labeled nucleotide bound to the nucleotide binding site of the polymerase. 10. The composition of claim 1 , wherein the nanoparticle comprises a nanocrystal comprising a semiconductor. 11. A composition, comprising a population of biomolecule-nanoparticle conjugates that include a polymerase linked to a nanoparticle, wherein an at least about 20% of the polymerase-nanoparticle conjugates in the population have an average of about 0.5-1.5 polymerase biomolecules per conjugate; wherein the nanoparticle is capable of generating a detectable signal. 12. The composition of claim 11 , comprising: a polymerase including a His-tag-linked to the nanoparticle via a His-tag mediated attachment. 13. The composition of claim 11 , wherein at least about 40% of the biomolecule-nanoparticle conjugates in the population are monodisperse conjugates. 14. The composition of claim 11 , wherein the biomolecule is a polymerase. 15. The composition of claim 11 , further comprising an accessory compound selected from among uracil DNA glycosylase, uracil DNA glycosylase, maltose binding protein, albumin, avidin, chloramphenicol acetyltransferase, horseradish peroxidase, glutathione S-transferase and mucin. 16. The composition of claim 15 , wherein the accessory compound is a protein that does not react with a polymerase or nucleotides. 17. The composition of claim 11 , wherein the nanoparticle comprises a nanocrystal comprising a semiconductor. 18. The composition of claim 1 , wherein the polymerase comprises a His tag. 19. The composition of claim 1 , wherein the polymerase comprises one member of a binding pair and the nanoparticle comprises a complementary member of the binding pair. 20. The composition of claim 1 , wherein the polymerase is a DNA polymerase. 21. The composition of claim 20 , wherein the DNA polymerase is at least 95% identical to a DNA polymerase selected from the group consisting of: Phi-29 DNA polymerase, B103 DNA polymerase, the Klenow fragment of E. coli DNA polymerase and HIV reverse transcriptase. 22. The composition of claim 1 , wherein the polymerase link is selected from one of a group consisting of: covalent bonding, affinity bonding and electrostatic bonding. 23. The composition of claim 1 , wherein the nanoparticle has a surface coating including a ligand selected from the group consisting of: a DHLA-based ligand, a polycyclic acid-based ligand, a bipeptide ligand and a tridentate thiol-based ligand. 24. The composition of claim 1 , where the polymerase includes an N-terminal cysteine, and where N-terminal cysteine is linked to the nanoparticle through a covalent bond.

Assignees

Inventors

Classifications

  • C07H19/20Primary

    with the saccharide radical esterified by phosphoric or polyphosphoric acids · CPC title

  • DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

  • Nucleotidyltransferases (2.7.7) · CPC title

  • Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53) · CPC title

  • DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11015220B2 cover?
Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity. Such conjugates can exhibit reduced aggregation and improved stochi…
Who is the assignee on this patent?
Life Technologies Corp
What technology area does this patent fall under?
Primary CPC classification C07H19/20. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).